Alto Neuroscience (NYSE:ANRO – Get Free Report) posted its earnings results on Tuesday. The company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.13, FiscalAI reports.
Alto Neuroscience Stock Performance
ANRO stock traded up $2.04 during midday trading on Wednesday, reaching $30.65. 52,593 shares of the company’s stock traded hands, compared to its average volume of 428,165. The company has a current ratio of 14.85, a quick ratio of 14.85 and a debt-to-equity ratio of 0.07. Alto Neuroscience has a 52-week low of $10.80 and a 52-week high of $37.48. The stock has a market cap of $1.20 billion, a P/E ratio of -12.67 and a beta of 1.42. The stock’s 50-day moving average is $26.71 and its 200 day moving average is $24.43.
Wall Street Analyst Weigh In
Several equities analysts have commented on the company. Wedbush raised their price objective on Alto Neuroscience from $24.00 to $26.00 and gave the company a “neutral” rating in a research report on Thursday, August 13th. Wall Street Zen downgraded shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday, September 12th. BTIG Research increased their price target on shares of Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Zacks Research raised shares of Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Tuesday, October 27th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Alto Neuroscience currently has an average rating of “Moderate Buy” and an average target price of $37.88.
View Our Latest Analysis on ANRO
Insider Activity
In other news, CFO Nicholas Smith sold 24,056 shares of the company’s stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $25.82, for a total value of $621,125.92. Following the completion of the sale, the chief financial officer directly owned 24,060 shares in the company, valued at $621,229.20. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 11.25% of the stock is currently owned by insiders.
About Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto’s approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.
Featured Stories
- Five stocks we like better than Alto Neuroscience
- Alphabet Escalates AI Chip Rivalry With NVIDIA
- Amazon’s Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?
- 3 Stocks Wall Street Likes More Than the Market Does
- Anthropic’s Trillion-Dollar IPO Could Give Cloud Giants a Double Win
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
